MINNEAPOLIS, Aug. 12, 2009 (GLOBE NEWSWIRE) -- Charles H. Johnson & Associates announces that a class action has been commenced in the United States District Court for the Southern District of Texas on behalf of purchasers of Repros Therapeutics, Inc. ("Repros" or the "Company") (Nasdaq:RPRX) publicly traded securities during the period July 1, 2009 through August 3, 2009 (the "Class Period").
If you are a member of the proposed Class, you may move the Court to serve as a lead plaintiff for the Class on or before October 6, 2009. You do not need to be a lead plaintiff in order to share in any recovery that may be obtained.
The Complaint alleges that Repros concealed the extent of the serious adverse events suffered by patients in its clinical trials for the drug Proellex. On July 1, 2009, Repros issued a press release stating that the drug showed substantial promise and had minimal side effects. However, Proellex elevated liver enzymes to dangerous levels. By August 3, 2009, the extent of these problems was fully revealed, and Repros announced the cancellation of the clinical trial. During that time, the price of Repros dropped over 73% from a close of $4.96 per share on July 1, 2009 to a close of $1.31 per share on August 3, 2009.
If you purchased Repros Therapeutics, Inc. stock during the Class Period, or have any questions concerning this notice or your rights with respect to this matter, please contact:
Neal Eisenbraun, Esq. (cjohnsonlaw@gmail.com) Charles H. Johnson & Associates 2599 Mississippi Street New Brighton, MN 55112 (651) 633-5685